Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
$39.79
$28.86
$43.12
$2.38B1.04166,711 shs313,900 shs
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$3.90
-0.5%
$3.99
$3.21
$7.18
$937.88M0.64.48 million shs5.18 million shs
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$20.51
-1.1%
$23.38
$13.22
$47.48
$1.19B-1.87836,373 shs425,852 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$36.75
-0.1%
$33.57
$27.12
$60.90
$2.20B2.41963,366 shs681,244 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
0.00%0.00%0.00%0.00%0.00%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+6.23%+7.99%+5.38%-18.16%-47.10%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-1.61%-6.15%-4.51%+31.35%-47.19%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.39%+4.13%+24.63%-5.52%-25.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.2792 of 5 stars
3.53.00.04.41.52.50.6
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.6181 of 5 stars
3.53.00.00.02.01.70.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.3344 of 5 stars
4.42.00.04.42.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
0.00
N/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$10.89179.20% Upside
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
3.00
Buy$76.17271.36% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4037.14% Upside

Current Analyst Ratings Breakdown

Latest AMEH, TWST, GPCR, and ARDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$65.00
6/23/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$89.00
6/18/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
5/12/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $75.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
5/2/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$11.00
5/2/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
$1.14B0.00N/A32.51$9.60 per share0.00
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M2.80N/AN/A$0.73 per share5.34
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$15.10 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M7.04N/AN/A$8.07 per share4.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
$45.17M$1.0040.820.001.153.56%9.90%5.51%N/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.22N/A12.58N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$122.53M-$0.87N/AN/AN/AN/A-16.35%-15.71%8/6/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)

Latest AMEH, TWST, GPCR, and ARDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.24-$0.27-$0.03-$0.27N/AN/A
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
N/AN/AN/AN/AN/A
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
0.35
2.35
2.35
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.04
4.12
3.81
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
23.29
23.29
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
35.88%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
8.46%
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
9.43%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apollo Medical Holdings, Inc. stock logo
AMEH
Apollo Medical
1,36258.28 million53.35 millionOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90239.26 million227.77 millionOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13657.34 million51.94 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apollo Medical stock logo

Apollo Medical NASDAQ:AMEH

Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare company, provides medical care services in the United States. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was incorporated in 1985 and is headquartered in Alhambra, California.

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$3.90 -0.02 (-0.51%)
Closing price 04:00 PM Eastern
Extended Trading
$3.92 +0.02 (+0.51%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$20.51 -0.23 (-1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$21.10 +0.59 (+2.90%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$36.75 -0.04 (-0.11%)
Closing price 04:00 PM Eastern
Extended Trading
$36.95 +0.20 (+0.54%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.